2021. 06. 21
SK invested about 150 billion won in the expansion of existing vaccine manufacturing plants used for cell culture, genetic recombination, etc. as well as the establishment of new vaccine platform facilities for materials such as mRNA
The additional purchase of a site approximately 99,130㎡ in size for factory expansion represents a “Leap to a global vaccine production hub”
North Gyeongsang Province and Andong pledged administrative cooperation and financial support in this public-private partnership to foster the vaccine industry
Ahn Jae-yong, CEO of SK bioscience (center), Lee Chul-woo, the governor of North Gyeongsang Province (left), and Kwon Young-se, mayor of Andong, are signing an MOU for expansion of the L house and the purchase of the expansion site.
SK bioscience has begun full-fledged
steps to become a hub for global vaccine production.
SK bioscience (CEO: Ahn Jae-yong)
announced on the 21st that it signed a Memorandum of Understanding
(MOU) with Andong (Mayor: Kwon Young-se) and North Gyeongsang Province
(Governor: Lee Cheol-woo) to invest in expanding plants and sites at L House,
its vaccine plant located in Andong, North Gyeongsang Province.
This MOU was promoted to secure
additional sites for plants and to expand cutting-edge vaccine facilities to
reflect the increased demand for vaccines produced by SK bioscience, which has
grown into a global company by supplying COVID-19 vaccines around the world.
According to the MOU, SK bioscience
will invest about 150 billion won by 2024 to expand the manufacturing
facilities of L House, which has the latest vaccine production facilities for
processes such as cell culture, bacterial culture, gene recombination, and
protein conjugation, and build new platform facilities for handling materials
including mRNA and next-generation viral vectors.
Also, the company will expand the
plant by about 161,000 m2 by purchasing an additional site of about
99,130 m2 within the Gyeongbuk Bio 2nd General Industrial
Complex, which is being built in Maegok-ri, Pungsan-eup, Andong, near the
existing L-House site.
North Gyeongsang Province and Andong
will actively support SK bioscience´s investment to ensure success.
In particular, Andong decided to
actively implement the city´s project for promoting employment, which calls for
fostering professional workers capable of contributing to the development of
the industry at the expanded vaccine plant. Companies conducting training and
exercises for personnel will be partially supported by local governments for
With this plant expansion, SK
bioscience plans to expand its business and solidify its leading position
within the Korean market as well as establish itself as a hub for global
SK bioscience expects L House´s
COVID-19 vaccine manufacturing facilities to gain momentum in its expansion
into global business since it recently acquired the EU-Good Manufacturing
Practice (GMP) certificate. The company’s flu and chickenpox vaccines have also
been certified by the World Health Organization (WHO)’s Prequalification (PQ)
Lee Cheol-woo, the governor of North
Gyeongsang Province, said, “I am proud that a global vaccine company continues
to invest and promote employment in our region.” He added, “With SK bioscience,
we will nurture the northern regions of Gyeongbuk, including Andong, as
outposts for the vaccine industry, while concentrating on job creation so that
no young people leave the region due to a lack of employment opportunities.”
Kwon Young-se, Andong Mayor, said,
“The best welfare is to create quality jobs. We will support SK bioscience in
cementing its position as a global vaccine leader so that Andong can join the
top 5 vaccine powerhouses.”
Ahn Jae-yong, CEO of SK bioscience, said, “For the Korean vaccine industry to become a hub for global vaccine production, the national government, local governments, and companies need to cooperate in creating a strategy for growth, and this MOU is a good example of that,” and “We will make Andong the center of global vaccine production through L House.”